Home » Newsletters » BioWorld Science

BioWorld Science

March 22, 2002

View Archived Issues

Daiichi decides not to seek marketing approval for nefiracetam in Japan

Development of memantine in Japan extended to mild to moderate AD under new agreement

Corus receives orphan drug designation for inhaled antibiotic in CF patients

HIV entry inhibitor effective as salvage therapy in patients failing conventional treatment

Potential utility of Antrin photoangioplasty further supported by data presented during ACC meeting

Efficacy of etoricoxib significantly superior to placebo in the treatment of chronic low back pain

Prague presentations describe good anti-HBV activity and favorable pharmacokinetics of MIV-210

TAS-108, a safer antiestrogen for breast cancer

Xenova offers a profile of its achievements in 2001

Oral entecavir highly effective in transgenic mouse model of HBV infection

First oral drug developed to treat smallpox infection

Schering-Plough searches for new antibiotics using genomic-derived targets

Cell Genesys discontinues p27/p16 gene therapy collaboration

Monoclonal antibodies for treating autoimmune conditions claimed by Immunex

Schering AG to acquire Collateral Therapeutics

Scientists at Takeda present new factor Xa inhibitors

Novel GnRH antagonists for sex hormone-dependent conditions identified at GSK

Selective COX-2 inhibitors reported in a recent patent from Roche

New antiviral compounds disclosed by Bayer

GlaxoSmithKline presents new compounds for inflammatory and allergic conditions

Daclizumab fails to meet endpoint as maintenance treatment in psoriasis

Nicotinic cholinergic receptors from Targacept have potential for a wide variety of CNS disorders

Research at Corixa leads to new hepatitis B and influenza vaccines

CPMP recommends approval of Tamiflu for influenza in E.U.

FDA approval for Avinza for once-daily treatment of chronic pain

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...